Molecular biology of the androgen receptor

Journal of Clinical Oncology

Volumn 20, Issue 13, 2002, Pages 3001-3015

  Gelmann, Edward P ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CHAPERONE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DNA; HEAT SHOCK PROTEIN; MESSENGER RNA; PROTEIN P160; RNA POLYMERASE; TRANSCRIPTION FACTOR;

AMINO ACID SEQUENCE; CANCER GROWTH; CHROMOSOME XQ; DISEASE SEVERITY; GENE MUTATION; GENETIC PREDISPOSITION; HORMONE RESPONSIVE ELEMENT; HUMAN; LIGAND BINDING; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONFORMATION; PROTEIN DNA BINDING; PROTEIN DOMAIN; REVIEW; TATA BOX; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRINUCLEOTIDE REPEAT;

ADENINE; ANIMALS; CYTOSINE; GUANINE; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RISK; TRANSCRIPTION, GENETIC; TRINUCLEOTIDE REPEATS;

EID: 0036645414     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.10.018     Document Type: Review

References (191)

1. Regulation of androgen action
2. Collocation of androgen receptor gene mutations in prostate cancer
3. Androgen-receptor-interacting nuclear proteins
4. Clinical review 134: The endocrinology of prostate cancer
5. Androgen receptors in prostate cancer
6. Androgen receptor mutations in prostate cancer
7. Androgen receptor defects: Historical, clinical, and molecular perspectives
8. Androgen receptor: An overview
9. The androgen receptor: An overview
10. Molecular mechanisms of androgen action
11. Complete androgen insensitivity syndrome: Long-term medical, surgical, and psychosexual outcome
12. Cloning of human androgen receptor complementary DNA and localization to the X chromosome
13. Androgen receptor locus on the human X chromosome: Regional localization to Xql 1-12 and description of a DNA polymorphism
14. Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity
15. Structural organization of the human androgen receptor gene
16. Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter: The role of Sp 1
17. Characterization and expression of a cDNA encoding the human androgen receptor
18. The androgen receptor gene is located on a highly conserved region of the X chromosomes of marsupial and monotreme as well as eutherian mammals
19. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy
20. Evolution of the primate androgen receptor: A structural basis for disease
21. Sequence variation in the androgen receptor gene is not a common determinant of male sexual orientation
22. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer
23. The molecular mechanisms of neuronal apoptosis
24. Polyglutamine-mediated aggregation and cell death
25. Chaperones Hsp 70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract
26. Caspases that are activated during generation of nuclear polyglutamine aggregates are necessary for DNA fragmentation but not sufficient for cell death
27. Expression of expanded repeat androgen receptor produces neurologic disease in transgenic mice
28. A distal activation domain is critical in the regulation of the rat androgen receptor gene promoter
29. The mouse androgen receptor gene contains a second functional promoter which is regulated by dihydrotestosterone
30. A novel regulatory element associated with age-dependent expression of the rat androgen receptor gene
31. Androgen receptor messenger ribonucleic acid (mRNA) in the rat liver: Changes in mRNA levels during maturation, aging, and calorie restriction
32. The rat androgen receptor gene promoter
33. The rat androgen receptor: Primary structure, autoregulation of its messenger ribonucleic acid, and immunocytochemical localization of the receptor protein
34. Autologous down-regulation of androgen receptor messenger ribonucleic acid
35. Transient down-regulation of androgen receptor messenger ribonucleic acid (mRNA) expression in Sertoli cells by follicle-stimulating hormone is followed by up-regulation of androgen receptor mRNA and protein
36. Transcriptional regulation of androgen receptor gene expression in Sertoli cells and other cell types
37. Regulation of the 5′-flanking region of the mouse androgen receptor gene by cAMP and androgen
38. Identification of 3′,5′-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter
39. Evolution of the androgen receptor: Structure-function implications
40. Evolution of the primate androgen receptor: A structural basis for disease
41. Structural evidence for ligand specificity in the binding domain of the human androgen receptor: Implications for pathogenic gene mutations
42. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T 877A mutant complexed with the natural agonist dihydrotestosterone
43. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
44. Molecular basis of agonism and antagonism in the oestrogen receptor
45. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains
46. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma
47. The AF 1 and AF2 domains of the androgen receptor interact with distinct regions of SRCI
48. The androgen receptor amino-terminal domain plays a key role in p 160 coactivator-stimulated gene transcription
49. Solution structure of the glucocorticoid receptor DNA-binding domain
50. The basis for half-site specificity explored through a non-cognate steroid receptor-DNA complex
51. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA
52. Solution structure of the DNA-binding domain of the oestrogen receptor
53. The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: How receptors discriminate between their response elements
54. Structural determinants of nuclear receptor assembly on DNA direct repeats
55. Differential DNA binding by the androgen and glucocorticoid receptors involves the second Zn-finger and a C-terminal extension of the DNA-binding domains
56. Interaction of the glucocorticoid receptor DNA-binding domain with DNA as a dimer is mediated by a short segment of five amino acids
57. Determinants of DNA sequence specificity of the androgen, progesterone, and glucocorticoid receptors: Evidence for differential steroid receptor response elements
58. Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA
59. Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene
60. Androgen-specific gene activation via a consensus glucocorticoid response element is determined by interaction with nonreceptor factors
61. Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene
62. The stringency and magnitude of androgen-specific gene activation are combinatorial functions of receptor and nonreceptor binding site sequences
63. Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer
64. Analysis of the DNA-binding affinity, sequence specificity and context dependence of the glucocorticoid receptor zinc finger region
65. Determinants of high-affinity DNA binding by the glucocorticoid receptor: Evaluation of receptor domains outside the DNA-binding domain
66. Two classes of androgen receptor elements mediate cooperativity through allosteric interactions
67. Transcriptional activation and nuclear targeting signals of the human androgen receptor
68. Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity
69. Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer
70. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor
71. Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II)
72. Interaction of human thyroid hormone receptor beta with transcription factor TFIIB may mediate target gene derepression and activation by thyroid hormone
73. Distinct TFIID complexes mediate the effect of different transcriptional activators
74. Different TBP-associated factors are required for mediating the stimulation of transcription in vitro by the acidic transactivator GAL-VP 16 and the two nonacidic activation functions of the estrogen receptor
75. Interaction of the human androgen receptor transactivation function with the general transcription factor TFIIF
76. Interactions between the retinoid X receptor and a conserved region of the TATA-binding protein mediate hormone-dependent transactivation
77. Nuclear import of the human androgen receptor
78. Transforming growth factor-betal induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells
79. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor: Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences
80. Phosphorylation of steroid hormone receptors
81. Regulation of progesterone receptor-mediated transcription by phosphorylation
82. Hormonal regulation and identification of chicken progesterone receptor phosphorylation sites
83. Phosphorylation of the androgen receptor by a nuclear cAMP-independent protein kinase
84. Phosphotryptic peptide analysis of the human androgen receptor: Detection of a hormone-induced phosphopeptide
85. Mechanisms of androgen receptor activation and function
86. Identification of three proline-directed phosphorylation sites in the human androgen receptor
87. Identification of a novel phosphorylation site in human androgen receptor by mass spectrometry
88. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity
89. Androgen blocks apoptosis of hormone-dependent prostate cancer cells
90. The nuclear receptor superfamily: The second decade
91. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
92. Steroid requirement for androgen receptor dimerization and DNA binding: Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains
93. Nuclear receptor coactivators
94. Nuclear receptor coactivators and corepressors
95. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor
96. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
97. Formation of the androgen receptor transcription complex
98. Structure and specificity of nuclear receptor-coactivator interactions
99. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma
100. Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators
101. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation
102. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors
103. CREB-binding protein in androgen receptor-mediated signaling
104. Global transcription regulators of eukaryotes
105. Increasing the complexity of coactivation in nuclear receptor signaling
106. Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain
107. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2)
108. Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators
109. Specificity of ligand-dependent androgen receptor stabilization: Receptor domain interactions influence ligand dissociation and receptor stability
110. Multiple receptor domains interact to permit, or restrict, androgen-specific gene activation
111. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor
112. Androgen-induced NH2- and COOH-terminal interaction inhibits p 160 coactivator recruitment by activation function 2
113. The FXXLF motif mediates androgen receptor-specific interactions with coregulators
114. Androgen-insensitivity syndrome as a possible coactivator disease
115. Androgen resistance: The clinical and molecular spectrum
116. Activation of programmed cell death in the rat ventral prostrate after castration
117. The prostate in eunuchs
118. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide
119. The inhibitory effect of 4-hydroxyphenyl retinamide (4-HPR) on metastasis of prostate adenocarcinoma-III cells in Lobund-Wistar rats
120. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium
121. Serum testosterone and dihydrotestosterone in carcinoma of the prostate
122. Blood hormone profiles in prostate cancer patients in high risk and low risk populations
123. Plasma steroids in benign prostatic hypertrophy and carcinoma of the prostate
124. Abnormal levels of plasma hormones in men with prostate cancer: Evidence toward a "two-disease" theory
125. Androgen concentration in blacks with benign and malignant prostatic disease
126. Prediagnostic serum hormones and the risk of prostate cancer
127. Aberrant androgen action and increased size of tandem CAG repeat in androgen receptor gene in X-linked recessive bulbospinal neuronopathy
128. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: Specificity in prostate and non-prostate cell lines
129. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length
130. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer
131. Androgen receptor CAG repeat lengths in prostate cancer: Correlation with age of onset
132. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk
133. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression
134. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: A population-based case-control study in China
135. (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population
136. The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer
137. Identification of two germline point mutations in the 5'UTR of the androgen receptor gene in men with prostate cancer
138. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol
139. Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene
140. The Finnish R726L audrogen receptor mutation is uncommon in prostate cancer families in the United States
141. Studies on prostatic cancer: II. The effect of castration on clinical patients with carcinoma of the prostate
142. Studies on prostatic cancer: Effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
143. Immunohistochemical study of androgen receptors in metastatic prostate cancer: Comparison of receptor content and response to hormonal therapy
144. Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer
145. Relationship between concentrations of extractable and matrix-bound nuclear androgen receptor and clinical response to endocrine therapy for prostatic adenocarcinoma
146. Relationship between androgen receptor binding activity in human prostate cancer and clinical response to endocrine therapy
147. Relationship of androgen receptors to the growth and regression of the prostate
148. Predicting response of prostatic carcinoma to endocrine therapy
149. Cancer surveillance series: Interpreting trends in prostate cancer - Part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates
150. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
151. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
152. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
153. Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer
154. Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients
155. Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma
156. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer
157. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer
158. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade
159. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer
160. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens
161. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: High affinity for progestagenic and estrogenic steroids
162. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens
163. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens
164. The LNCaP line: A new model for studies on human prostatic carcinoma
165. Functional analysis of 44 mutant androgen receptors from human prostate cancer
166. Androgen receptor mutations in prostate cancer
167. Androgen receptor mutations in prostate cancer
168. Androgen receptor gene mutations in prostate cancer: Implications for disease progression and therapy
169. Androgen receptor gene mutations in prostate cancer
170. Androgen receptor gene mutations in human prostate cancer
171. Androgen receptor gene mutations in human prostate cancer
172. Androgen receptor gene mutations in hormone-refractory prostate cancer
173. Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer
174. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer
175. Precise microdissection of human prostate cancer reveals genotypic heterogeneity
176. Androgen receptor mutations in prostate cancer
177. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence
178. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist
179. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a
180. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells
181. A canonical structure for the ligand-binding domain of nuclear receptors
182. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen
183. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy
184. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function
185. Prostate cancer in a transgenic mouse
186. Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region
187. Hormone therapy of advanced prostate cancer: Where we stand today
188. The effect of finasteride in men with benign prostatic hyperplasia
189. Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: A prospective study
190. Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone
191. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness